Excessive Daytime Sleepiness Clinical Trials

Find Excessive Daytime Sleepiness Clinical Trials Near You

Epidemiology of Narcolepsy Type 1 and Type 2 in Spain

Status: Recruiting
Location: See all (10) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY

The main purpose of this study is to find out how many people in Spain have been diagnosed with narcolepsy type 1 and type 2, and how many new participants are diagnosed each year. Narcolepsy is a rare sleep disorder that causes excessive daytime sleepiness. The researchers will look at medical records from hospitals across Spain to count participants with these conditions and understand patterns in diagnosis over time.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Participants with NT1 or NT2 following International Classification of Sleep Disorders, 3rd Edition (ICSD-3) or ICSD-3 text revision (ICSD-3-TR) criteria who are alive at any point during 2023 or 2024.

• Any age, ethnicity and nationality.

• Treated / under follow-up in the study site and residing in the hospitals' reference areas. Consideration will be given if participants have changed their address or reached adulthood.

• Confirmation to have a diagnosis of NT1 or NT2 by a specialist.

• Participants greater than equal to (≥) 18 years or parents of narcolepsy participants under 18 years of age.

• Any gender, ethnicity or nationality.

• Residence in Spain.

Locations
Other Locations
Spain
Hospital de la Ribera
NOT_YET_RECRUITING
Alzira
Hospital Clinic de Barcelona
RECRUITING
Barcelona
Hospital Vall d'Hebrón
NOT_YET_RECRUITING
Barcelona
Hospital General de Castellón
NOT_YET_RECRUITING
Castellon
Hospital Virgen de las Nieves
NOT_YET_RECRUITING
Granada
Hospital Clínico San Carlos
ACTIVE_NOT_RECRUITING
Madrid
Hospital La Paz
NOT_YET_RECRUITING
Madrid
Hospital de Navarra
NOT_YET_RECRUITING
Pamplona
Hospital Virgen Macarena
RECRUITING
Seville
Hospital de Araba
NOT_YET_RECRUITING
Vitoria-gasteiz
Contact Information
Primary
Takeda Contact
medinfoUS@takeda.com
+1-877-825-3327
Time Frame
Start Date: 2025-12-02
Estimated Completion Date: 2026-05-30
Participants
Target number of participants: 100
Treatments
Core Group
Participants with Narcolepsy Type (NT1) and Narcolepsy Type (NT2) of any age, ethnicity and nationality, treated / under follow-up in approximately 10 Spanish public hospitals, who are alive at any point during 2023 or 2024, residing in the hospitals' reference areas will be retrospectively observed through chart reviews. The retrospective data for up to approximately 10 years would be assessed.
Supplementary Group
Participants with NT1 and NT2 from Spain will undergo an online survey conducted in collaboration with a patient advocacy group.
Sponsors
Leads: Takeda

This content was sourced from clinicaltrials.gov